|
| Press Releases |
|
 |
|
| Thursday, January 2, 2025 |
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy |
| Everest Medicines (HKEX 1952.HK, Everest , or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that with the official implementation of the latest update of the National Reimbursement Drug List ('NRDL') on January 1, 2025, NEFECON will apply the NRDL pricing, which will benefit more IgA nephropathy (IgAN) patients. more info >> |
|
|
新版國家醫保藥品目錄落地 全球首個IgA腎病對因治療藥物耐賦康(R)納入報銷 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈隨著《國家基本醫療保險、工傷保險和生育保險藥品目錄（2024年）》（「國家醫保藥品目錄」）2025年1月1日正式實施，耐賦康(R)（布地奈德腸溶膠囊，NEFECON(R)）將開始執行醫保新價格，各地IgA腎病患者將陸續享受醫保報銷。 more info >> |
|
|
新版国家医保药品目录落地 全球首个IgA肾病对因治疗药物耐赋康(R)纳入报销 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布随着《国家基本医疗保险、工伤保险和生育保险药品目录（2024年）》（"国家医保药品目录"）2025年1月1日正式实施，耐赋康(R)（布地奈德肠溶胶囊，NEFECON(R)）将开始执行医保新价格，各地IgA肾病患者将陆续享受医保报销。 more info >> |
|
| Wednesday, December 18, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription for VELSIPITY(R) has been written at Foshan Fosun Chancheng Hospital in Guangdong, under the "Hong Kong and Macau Medicine and Equipment Connect" policy, which marks the official beginning of this new therapy benefiting patients in mainland China. more info >> |
|
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）大灣區內地首張處方在佛山正式落地 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈伊曲莫德（VELSIPITY(R), etrasimod）通過「港澳藥械通」政策，在廣東佛山複星禪誠醫院開出粵港澳大灣區內地首張處方，標誌著伊曲莫德開始正式惠及中國大陸患者。 more info >> |
|
|
云顶新耀宣布伊曲莫德（VELSIPITY(R)）大湾区内地首张处方在佛山正式落地 |
| 云顶新耀（HKEX 1952.HK）是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，今日宣布伊曲莫德（VELSIPITY(R), etrasimod）通过“港澳药械通”政策，在广东佛山复星禅诚医院开出粤港澳大湾区内地首张处方，标志着伊曲莫德开始正式惠及中国大陆患者。 more info >> |
|
| Tuesday, December 17, 2024 |
|
|
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the National Medical Products Administration (NMPA) of China has officially accepted the New Drug Application (NDA) for VELSIPITY (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). VELSIPITY is an effective and convenient, once-daily, oral treatment for patients with moderately to severely active UC. more info >> |
|
|
雲頂新耀宣佈中國國家藥品監督管理局正式受理伊曲莫德（VELSIPITY(R)） |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈中國國家藥品監督管理局已正式受理伊曲莫德（VELSIPITY(R)）用於治療中重度活動性潰瘍性結腸炎（UC）患者的新藥上市許可申請（NDA）。 more info >> |
|
| Thursday, December 12, 2024 |
|
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIPITY(R) (etrasimod) has been issued on December 11th at Kiang Wu Hospital in Macau. more info >> |
|
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）在中國澳門的首張處方落地 |
| 雲頂新耀（HKEX 1952.HK）是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司，今日宣佈伊曲莫德（VELSIPITY(R), etrasimod）於12月11日在中國澳門鏡湖醫院開出首張處方，這也是伊曲莫德在雲頂新耀亞洲授權區內獲批後開出的首張處方，標誌著這款自身免疫性疾病領域的重磅產品正式開始惠及亞洲患者。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
三菱造船と日本製鉄が低圧液化CO₂タンクの新規鋼材と熱処理（PWHT）省略技術を開発
Dec 5, 2025 11:30: JST
|
|
|
LEXUS、バッテリーEVスポーツカーのコンセプトモデル「Lexus LFA Concept」を世界初公開
Dec 5, 2025 11:20: JST
|
|
|
Doubleview Extends High-Grade Domains at Hat: H099 Returns 438m of 0.40% CuEq Including 52m of 1.02% CuEq, Expanding Mineralization Envelope Around Conceptual Pit Vertically and Laterally
Dec 4, 2025 21:59 HKT/SGT
|
|
|
Business of IP Asia (BIP Asia) Forum and Entrepreneur Day open today
Dec 4, 2025 21:00 HKT/SGT
|
|
|
CaoCao Unveils '100 Cities, 100 Billion in 10 Years' Robotaxi Strategy, Officially Launches World's First 'Green Intelligent Mobility Hub'
Dec 4, 2025 21:00 HKT/SGT
|
|
|
曹操出行發佈Robotaxi「十年百城千億」戰略目標 全球首個「綠色智慧通行島」正式啟用
Dec 4, 2025 18:18 HKT/SGT
|
|
|
The Gourmet's Guide: Using Your TravelKon eSIM to Hunt for Japan's Best Ramen, Sushi, and Street Food
Dec 4, 2025 17:45 HKT/SGT
|
|
|
Oman's 10-Year Golden Residency Program Attracts Global Investors Seeking Stability and Long-Term Access
Dec 4, 2025 16:19 HKT/SGT
|
|
|
Spritzer Celebrates Global and Regional Brand Excellence 2025
Dec 4, 2025 12:45 HKT/SGT
|
|
|
Honda、新型「CR-V」の先行予約開始
Dec 4, 2025 11:30: JST
|
|
|
在聯泓格潤「超級工廠」看見綠色材料全鏈路
Dec 4, 2025 09:36 HKT/SGT
|
|
|
在联泓格润"超级工厂" 看见绿色材料全链路
Dec 4, 2025 09:14 HKT/SGT
|
|
|
阿曼十年黃金居留計劃吸引全球投資者尋求穩定與長期通達
Dec 4, 2025 08:00 HKT/SGT
|
|
|
阿曼十年黄金居留计划吸引全球投资者寻求稳定与长期准入
Dec 4, 2025 08:00 HKT/SGT
|
|
|
The 26th Hong Kong Forum marks successful completion
Dec 3, 2025 22:44: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
